Towards HCV elimination among people who inject drugs in Hai Phong, Vietnam: study protocol for an effectiveness-implementation trial evaluating an integrated model of HCV care (DRIVE-C: DRug use & Infections in ViEtnam-hepatitis C).
Clinical trials
Hepatology
Infection control
Public health
THERAPEUTICS
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
18 11 2020
18 11 2020
Historique:
entrez:
19
11
2020
pubmed:
20
11
2020
medline:
15
5
2021
Statut:
epublish
Résumé
In Vietnam, people who inject drugs (PWID), who are the major population infected by hepatitis C virus (HCV), remain largely undiagnosed and unlinked to HCV prevention and care despite recommended universal hepatitis C treatment. The data on the outcomes of HCV treatment among PWID also remain limited in resource-limited settings. The DRug use & Infections in ViEtnam-hepatitis C (DRIVE-C) study examines the effectiveness of a model of hepatitis C screening and integrated care targeting PWID that largely uses community-based organisations (CBO) in Hai Phong, Vietnam. In a wider perspective, this model may have the potential to eliminate HCV among PWID in this city. The model of care comprises large community-based mass screening, simplified treatment with direct-acting antivirals (DAAs) and major involvement of CBO for PWID reaching out, linkage to care, treatment adherence and prevention of reinfection. The effectiveness of DAA care strategy among PWID, the potential obstacles to widespread implementation and its impact at population level will be assessed. A cost-effectiveness analysis is planned to further inform policy-makers. The enrolment target is 1050 PWID, recruited from the DRIVE study in Hai Phong. After initiation of pan-genotypic treatment consisting of sofosbuvir and daclatasvir administrated for 12 weeks, with ribavirin added in cases of cirrhosis, participants are followed-up for 48 weeks. The primary outcome is the proportion of patients with sustained virological response at week 48, that will be compared with a theoretical expected rate of 70%. The study was approved by Haiphong University of Medicine and Pharmacy's Ethics Review Board and the Vietnamese Ministry of Health. The sponsor and the investigators are committed to conducting this study in accordance with ethics principles contained in the World Medical Association's Declaration of Helsinki (Ethical Principles for Medical Research Involving Human Subjects). Informed consent is obtained before study enrolment. The data are anonymised and stored in a secure database. The study is ongoing. Results will be presented at international conferences and submitted to international peer-review journals. NCT03537196.
Identifiants
pubmed: 33208326
pii: bmjopen-2020-039234
doi: 10.1136/bmjopen-2020-039234
pmc: PMC7677340
doi:
Substances chimiques
Antiviral Agents
0
Pharmaceutical Preparations
0
Banques de données
ClinicalTrials.gov
['NCT03537196']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e039234Subventions
Organisme : NIDA NIH HHS
ID : R01 DA041978
Pays : United States
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Lancet. 2011 Aug 13;378(9791):571-83
pubmed: 21802134
Int J Drug Policy. 2016 Jun;32:50-6
pubmed: 27006257
Clin Infect Dis. 2013 Aug;57 Suppl 2:S39-45
pubmed: 23884064
J Urban Health. 2010 Mar;87(2):278-291
pubmed: 20041309
N Engl J Med. 2013 May 16;368(20):1907-17
pubmed: 23675659
J Gastroenterol Hepatol. 2012 Feb;27(2):238-47
pubmed: 22098550
J Med Virol. 2010 Aug;82(8):1355-63
pubmed: 20572071
Hepatology. 2012 Jan;55(1):49-57
pubmed: 21898506
AIDS Care. 2016 Oct;28(10):1312-5
pubmed: 27178119
Med Care. 2012 Mar;50(3):217-26
pubmed: 22310560
Hepatol Int. 2007 Sep;1(3):387-93
pubmed: 19669334
Jpn J Infect Dis. 2011;64(6):537-9
pubmed: 22116339
J Gastroenterol Hepatol. 1994 Jul-Aug;9(4):416-9
pubmed: 7524723
Health Econ. 2016 Feb;25 Suppl 1:1-5
pubmed: 26804357
Hepatology. 2013 Apr;57(4):1333-42
pubmed: 23172780
Value Health. 2014 Jun;17(4):445-53
pubmed: 24969006
Asian Pac J Allergy Immunol. 2009 Jun-Sep;27(2-3):153-60
pubmed: 19839502
Int J Drug Policy. 2015 Oct;26(10):911-21
pubmed: 26298331
Hepatology. 2013 Nov;58(5):1598-609
pubmed: 23553643
Sci Rep. 2020 Apr 24;10(1):6999
pubmed: 32332986
J Viral Hepat. 2011 Jan;18(1):70-6
pubmed: 20196807
J Hepatol. 2015 Apr;62(1 Suppl):S87-99
pubmed: 25920094